***Jon Ralston's NV update this morning: "Trump is dead.

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Understanding RTX's Recent Market Movements RTX Corp has seen a notable shift in its market dynamics recently. The company's short interest, defined as the number of shares sold short but not yet covered, has decreased by 7.63% since the last reporting period. Currently, there are approximately 16.18 million shares sold short, equating to 1.21% of all shares available for...

Celebrate the Joy of Christmas with PrayerSong Bring Love Into Your Home with a PrayerSong for Your Family and Friends When the holiday season arrives, the focus shifts beyond material gifts. Instead, it’s about nurturing connections filled with love, faith, and meaningful moments. This Christmas, PrayerSong provides families with a unique opportunity to honor loved...

Analyzing Short Interest for Analog Devices As investors navigate the ever-changing stock market, understanding short interest can provide valuable insights into market sentiment regarding Analog Devices (NYSE: ADI). Recently, it was reported that Analog Devices has seen a notable increase of 4.11% in its short percent of float. Currently, there are approximately 7.52...

Understanding Clinical Trials and Their Importance Clinical trials serve as a fundamental pillar in advancing medical knowledge and enhancing patient care. These trials encompass a detailed and thorough process involving participant recruitment, intervention administration, data collection, and result analysis. The outcomes produced from clinical trials play a crucial...